BETA
Your AI-Trained Oncology Knowledge Connection!
sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL
AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.
3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.
Personalized Kidney Cancer Vaccines Provide Direction to Immune Therapy
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Expanding Key Kidney Cancer Research Areas Via Institutional Collaboration
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
FDA Accepts BLA, Grants Priority Review to Tab-Cel in EBV-Positive PTLD
Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.
KIM-1 May Predict Higher-Risk Disease in Kidney Cancer
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion
Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.
Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer
Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.
Key Advances Across Kidney Cancer Research and Management at KCRS 2025
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Early-Stage Kidney Cancer Trial Aims to Restore Anticancer Immunity
A phase 0 trial is seeking to assess the feasibility of aiding anticancer cells with cytokines to restore their function.
Highlighting Beneficial Adjuvant/Neoadjuvant Strategies for Kidney Cancer
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment
A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma
Data from the DREAMM 7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.
Breaking Down the Phase 2 LASER trial of 177Lu-PSMA-617 in Clear Cell RCC
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Praful Ravi, MB, BChir, MRCP, on the phase 2 LASER trial in RCC.
Applying Clinical Trials to Patient Cases: The Melanoma Landscape
Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.
177Lu-PSMA-617 Trial May Be Efficacious in Advanced PSMA-Expressing ccRCC
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.
Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM
Results from the phase 3 GMMG HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.
Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.
Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC
Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.
Research Consortium Aims to Accelerate Progress in Kidney Cancer Management
Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET
Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer
A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.
Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.
Elironrasib Earns FDA Breakthrough Designation for KRAS G12C-Mutant NSCLC
The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.
XmAb819 Targets Highly Expressed Protein in Clear Cell Renal Cell Carcinoma
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.
Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.
Novel CAR T-Cell Therapy Prioritizes Immune-Restoring Capability in RCC
“The therapy is designed to prevent CAR T-cell inactivation and to restore the antitumor immunity of the white blood cells that have gotten through the tumor,” said Wayne A. Marasco, MD, PhD.
DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC
Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.")
